P

Pieris Pharmaceuticals
D

PIRS

17.070
USD
0.07
(0.41%)
Market Closed
Volume
284
EPS
-1
Div Yield
-
P/E
-1
Market Cap
22,536,497
OverviewSignalsIdeasNews
Related Instruments
    A
    ADAP
    -0.00320
    (-0.54%)
    0.58680 USD
    A
    ALLO
    -0.19000
    (-7.71%)
    2.27500 USD
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    C
    CLLS
    -0.02000
    (-1.06%)
    1.87000 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    R
    RIGL
    -3.530
    (-12.78%)
    24.100 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    V
    VYGR
    -0.57000
    (-9.18%)
    5.64000 USD
    More
News

Title: Pieris Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.